Tuesday, August 22, 2017 8:36:52 PM
Corporate Action Notice
Dear Client,
This email notification is in regards to a voluntary reorganization specific to your holding in the security identified below, which is held in your Scottrade® account. If you choose to participate, you are required to reply to the Scottrade® Support Team* by 08/29/2017.
Company: Ekso Bionics Holdings Rights
CUSIP Number: 282644996
Scottrade® Account Number: -----
Offer Expiration Date: 08/31/2017
Additional correspondence on this voluntary reorganization may be available on the company’s website. We must receive instructions from you by the above mentioned reply date if you wish to participate in the offer. Instructions received after the reply date will be processed on a "best efforts" basis only. As a holder of your securities, we will forward your instructions to the agent or custodian, should you choose to participate. Please be advised that we cannot act without your instructions and will not be held liable for any instructions received after the reply date. Any information given by us either verbally or in writing, is intended as a guide and is not to be used as the basis for any decision regarding this offer.
You are responsible for full compliance with the terms of this offer. In the event of a discrepancy between these terms and the offer materials, please note the offer materials will prevail. No written instructions will be accepted. Verbal instructions (no voicemail) must be given directly to an investment consultant. For Scottrade to act on your behalf, the shares or funds must remain in your account through the payment date and must be fully settled and unrestricted. All accounts will incur a $25 fee to process your instructions (this fee does not apply to dividend elections). Please be advised that expiration dates are often extended and terms are subject to change without notice.
Please do not reply to this email. If you have any questions, contact your local Scottrade® Support Team at 866.351.7640.*
Sincerely,
Recent EKSO News
- Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024 • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal • GlobeNewswire Inc. • 04/12/2024 12:00:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2024 09:14:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:08:54 PM
- Ekso Bionics Reports Record Annual Revenue of $18.3 Million • GlobeNewswire Inc. • 03/04/2024 09:05:00 PM
- Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 05:16:39 PM
- Ekso Bionics Announces $4.6 Million Registered Direct Offering • GlobeNewswire Inc. • 01/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 10:23:43 PM
- Ekso Bionics Launches GaitCoach Software for EksoNR • GlobeNewswire Inc. • 01/08/2024 09:05:00 PM
- Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 01/04/2024 10:05:12 PM
- Ekso Bionics Receives CMS Coding Approval for Ekso Indego Personal • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29 • GlobeNewswire Inc. • 11/16/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:13:59 PM
- Centers for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego Personal • GlobeNewswire Inc. • 11/02/2023 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/26/2023 08:17:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:10:19 PM
- Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38% • GlobeNewswire Inc. • 10/26/2023 08:05:00 PM
- Ekso Bionics to Report Third Quarter 2023 Financial Results on October 26, 2023 • GlobeNewswire Inc. • 10/19/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 09:23:17 PM
- Ekso Bionics Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Include Personal Exoskeletons within a Medicare Benefit Category • GlobeNewswire Inc. • 09/27/2023 12:00:00 PM
- Ekso Bionics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/11/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2023 01:44:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2023 01:40:23 AM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM